Chemokine Therapeutics Corporation

British Canadian Biosciences Corp

Wex Pharmaceuticals Inc.

Donald Wong

Ahmed Merzouk

Hassan Salari

Helmut Heinrich Buschmann

Jose Miguel Vela Hernandez

Jose Manuel Baeyens

Walter Korz

Susan Lu

Abdelkrim Habi

The present disclosure describes the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogs/derivatives as well as their acceptable salts, for treating neuropathic pain resulting from chemotherapy. Methods, compositions, dose units and dose forms of tetrodotoxin related to the use are described.

Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy

The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example, and can be selected from a group consisting of hematopoietic stem cells, hematopoietic progenitor cells, primitive granulocytes, primitive erythroid cells, leukocytes, and neutrophils. In some embodiments, the activity can include the rate of multiplication of the cell or, where the cell is a quiescent cell, the binding can repress the activation of the quiescent cell. Other embodiments of the present invention are taught herein.

Chemokine mimetics synthesis and their use

The present invention is concerned with chemokine analogs, including IL-8 analogs, IP-10 analogs, MIP-1&#x3b1; analogs, RANTES analogs, I-309 analogs, MCP-1 analogs, and CCL28 analogs, that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and disorders. A therapeutically effective amount of the chemokine analog may be administered to a patient in need of such treatment.

Chemokine analogs for the treatment of human disease

Growing community of inventors

Vancouver, Canada

Donald Wong